Company

AstraZeneca (AZN) · Stockholm Insider

Company desk

AstraZeneca

AZN · XSTO

Health Care

British-Swedish biopharmaceutical company developing prescription medicines across oncology, CVRM, respiratory and rare disease.

On this issuerLeif Johansson · chair Pascal Soriot · CEO Aradhana Sarin · CFO

AstraZeneca PLCISIN GB0009895292LEI PY6ZZQWO2IZFZC3IOL08IR site

Show on Capital →Tape for this name Calendar for this name Export evidence pack

Some official sources are late. Only what arrived is shown.Newest data 5h ago

OBSMarket observation

Price and volume

AZN · daily bars · evidence marks

Public source

HISTORICAL BEHAVIOUR

Prepared print

T−60 → T0 → T+34

Loading replay…

THIS PRINT · HISTORICAL OUTCOMES · NOT A FORECAST

Aradhana Sarin · buy · 2026-09-13

+3,5 %

T+1 abs · +4,6 % vs OMX

+6,5 %

T+5 abs · +6,3 % vs OMX

+3,5 %

T+20 abs · +3,4 % vs OMX

—

T+60 abs

—

T+120 abs

Yahoo OHLC (Tier-3 / unofficial) when that is the bar source — not a licensed close.

Event replay uses prepared studies and bars already on the desk — not a forecast.

SAME-CLASS COHORT · NOT A FORECAST

n=504

Leadership buys · tracked universe

+1,0 % median T+5 vs OMXS30

+1,5 % median T+20 vs OMXS30

AstraZeneca

Price and volume

AstraZeneca, last 30 days: two approvals and four clinical risk-reduction results

Has this happened before?

Prior disclosed clusters

What changed

AstraZeneca: Enhertu approved in the EU as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer

Enhertu approved in EU for HER2-positive eBC

Peer register lanes

Disclosed capital — separate registers

Threshold film · Flaggning

Reported insider transactions

Announcements & filings

People

Themes

Related companies

Explore

AstraZeneca: Sonesitatug vedotin reduced the risk of death by 42% in 2nd- and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01

AstraZeneca: Imfinzi plus Imdelltra reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial

AstraZeneca: Ultomiris received accelerated approval in the US as first and only C5 complement inhibitor to reduce proteinuria in adults with primary immunoglobulin A nephropathy

AstraZeneca: Tezspire positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission

AstraZeneca and Oracle launch global AI collaboration to advance clinical trial optimisation and support better patient outcomes

AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, Imfinzi, Tagrisso and Orpathys

AstraZeneca announces new strategic collaboration with insitro to use advanced AI systems to develop transformative therapeutics for difficult to treat cardiometabolic diseases

AstraZeneca: Efzimfotase alfa showed numerical improvement in 6-Minute Walk Test achieving mean difference of 17.05 metres vs placebo in treatment-naïve adolescents, adults with HPP at week 25 in HICKORY Ph3 trial

AstraZeneca: Alexion to showcase Phase III data in hypophosphatasia and hypoparathyroidism at ASBMR 2026 Annual Meeting

AstraZeneca opens new global strategic R&D centre in Kendall Square, Cambridge, Massachusetts

AstraZeneca completes equity investment in Summit

AZ & DS collaboration with Summit for Datroway

Admission of Further Securities to Trading